Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.76%
#4 aPriori aPriori +108.27%
#5 Bedrock Bedrock +74.39%
#6 Cysic Cysic +49.09%
#7 Prom Prom +38.71%
#8 Playnance Playnance +35.10%
#9 COTI COTI +26.15%
#10 Nillion Nillion +24.13%
Coin of the day
Wrapped One Wrapped One
Innstillinger
Språk
NORSK
Valuta
USD
Tema
GlobeImmune, Inc. GlobeImmune, Inc.

GlobeImmune, Inc.

GBIM
Rangering i aksjer #42634
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and... GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$575.00
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel GlobeImmune, Inc. (GBIM)

Kategori

Healthcare
P/E-forhold for GlobeImmune, Inc. (GBIM)
P/E-forhold per 2026 TTM: 0
Ifølge GlobeImmune, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for GlobeImmune, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.